Research programme: tolerogenic vaccines - Idogen

Drug Profile

Research programme: tolerogenic vaccines - Idogen

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Idogen; Lund University
  • Class Dendritic cell vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 02 Jan 2017 Idogen plans a phase I/II trial for Haemophilia A in Sweden
  • 12 Dec 2016 The European Medicines Agency’s Committee for Orphan Medicinal Products recommends orphan drug designation to tolerogenic vaccine for Haemophilia A in Europe
  • 05 Dec 2016 Idogen has patent protection for additional aspects of using zebularine for the treatment of autoimmune diseases and rejection of transplanted organs in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top